Occludin Recombinant Rabbit Monoclonal Antibody (6H10L9), Invitrogen™

Description

• This antibody is predicted to react with equine, mouse, rabbit and rat based on sequence homology
• Intact IgG appears on a non-reducing gel as ∽150 kDa band and upon reduction generating a ∽25 kDa light chain band and a ∽50 kDa heavy chain
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• Occludin is a 65 kDa protein that can exist in a variety of phosphorylated forms, ranging up to approximately 82 kDa
• Occludin is thought to be involved in regulating both the localization and the function of occludin
• Polyunsaturated fatty acids are known to up-regulate occludin expression, increasing the transendothelial cell resistance and reducing the cellular permeability to large molecules
• The level of occludin varies greatly depending on tissue; in brain tissue, occludin is highly and continuously expressed at cell-cell contact sites, whereas non-neural tissues show lower expression and discontinuous distribution
• Overall structural features of the occludin protein are highly conserved in all the species examined
• Under-expression of tight junction proteins, including occludin, is a key molecular abnormality responsible for the increased permeability of tumor endothelial tight junctions, which contributes to brain tumor edemas.